Intracellular activity of the peptide antibiotic NZ2114: Studies with Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 8, 2010, Pages 1720-1724

  Brinch, Karoline Sidelmann ^a   Tulkens, Paul M ^b   Van Bambeke, Francoise ^b   Frimodt Møller, Niels ^c   Høiby, Niels ^d   Kristensen, Hans Henrik ^a  

^a NOVOZYMES A S   (Denmark)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c STATENS SERUM INSTITUT   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Antimicrobial peptides; Killing kinetics; Plectasin

Indexed keywords

DAPTOMYCIN; NZ 2114; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; PEPTIDE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MONOCYTE; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; BACTERIAL COUNT; CELL LINE; COMPARATIVE STUDY; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; CELL LINE; COLONY COUNT, MICROBIAL; DAPTOMYCIN; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MONOCYTES; PEPTIDES; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 77954708513     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq159     Document Type: Article

References (10)

1. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339: 520-32.
2. Lowy FD. Is Staphylococcus aureus an intracellular pathogen? Trends Microbiol 2000; 8: 341-3.
3. Barcia-Macay M, Seral C, Mingeot-Leclercq MP et al. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother 2006; 50: 841-51.
4. Torres MK, Draghi DC, Pillar CM et al. Activity of NZ2114 against staphylococcal and streptococcal isolates, including resistant phenotypes. In: Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2008. Abstract F1-3962. American Society for Microbiology,Washington, DC, USA.
5. Schneider T, Kruse T, Wimmer R et al. Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II. Science 2010; 328: 1168-72.
6. Andes D, Craig W, Nielsen LA et al. In vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection model. Antimicrob Agents Chemother 2009; 53: 3003-9.
7. Cosgrove SE, Fowler VG Jr. Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin InfectDis2008;46Suppl5: S386-93.
8. Lemaire S, Kosowska-Shick K, Julian K et al. Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis. Clin Microbiol Infect 2008; 14: 766-77.
9. Brinch KS, Sandberg A, Baudoux P et al. Plectasin shows intracellular activity against Staphylococcus aureus in human THP-1 monocytes and in a mouse peritonitis model. Antimicrob Agents Chemother 2009; 53: 4801-8.
10. Lemaire S, Van Bambeke F, Mingeot-Leclercq MP et al. Activity of three β-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus. J Antimicrob Chemother 2005; 55: 897-904.